Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Continued decline in opioid utilization in workers’ compensation

    by
    • Optum Workers' Comp
    | Dec 07, 2017
    Tag Icon
    Compounded Medications, Specialty Medications, FDA, Morphine Equivalent Dose, Opioids
    Our analysis of 2017 data has shown a 14 percent decline in opioid prescriptions compared with 2016. This decline is a product of our work through medication management programs and its stakeholders’ programs throughout the system. The regulatory and legislative environment has also focused on the decline of opioid analgesics. All opioid-related metrics have shown a decline, including a 12 percent decline in the number of claimants using opioids and a 17 percent decrease in morphine equivalents.


  • The role of medication-assisted treatment in the management of opioid use disorder

    by
    • Optum Workers' Comp
    | Dec 06, 2017
    Tag Icon
    Opioids
    The continued challenges associated with the unintended consequences of opioid analgesic use requires that all treatment options for opioid use disorder (OUD) be considered and implemented as required. OUD is defined by the American Psychiatric Association as a problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested by two or more adverse conditions resulting from opioid use, occurring within a twelve month period.


  • FDA approves first once-monthly medication-assisted treatment option for opioid use disorder

    by
    • Optum Workers' Comp
    | Dec 04, 2017
    Tag Icon
    FDA
    The U.S. Food and Drug Administration (FDA) has approved Sublocade™, the first once-monthly injectable buprenorphine product in an ongoing effort to encourage safe adoption and more widespread use of FDA-approved treatments to help those afflicted by opioid addiction. Sublocade is indicated to treat moderate-to-severe opioid use disorder (OUD) in adults who have already started treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. It should only be initiated after patients have been on a stable dose of buprenorphine treatment for a minimum of seven days.


  • Limbrel® capsules linked to potentially life-threatening health problems

    by
    • Optum Workers' Comp
    | Nov 28, 2017
    Tag Icon
    FDA
    The U.S. Food and Drug Administration (FDA) has issued a warning to consumers and health professionals regarding adverse events, including the potential for two life-threatening health problems associated with Limbrel. Limbrel is a prescription medical food used to manage the metabolic processes associated with osteoarthritis. The potential life-threatening medical conditions include drug-induced liver injury and hypersensitivity pneumonitis, a rare immune system disorder affecting the lungs.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.